Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Monday

Urogen Pharma (NASDAQ:URGN) will likely be releasing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Urogen Pharma to post earnings of ($0.65) per share and revenue of $39.9220 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 2, 2026 at 10:00 AM ET.

Urogen Pharma Stock Performance

NASDAQ URGN opened at $21.70 on Monday. The company has a market cap of $1.02 billion, a PE ratio of -6.27 and a beta of 1.34. The firm’s 50 day moving average price is $21.28 and its 200-day moving average price is $20.89. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $30.00.

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 7,373 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $145,174.37. Following the sale, the insider owned 144,985 shares of the company’s stock, valued at approximately $2,854,754.65. The trade was a 4.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Jason Drew Smith sold 7,479 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51. Following the completion of the transaction, the general counsel directly owned 51,326 shares of the company’s stock, valued at approximately $1,010,608.94. This represents a 12.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Urogen Pharma

Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its position in Urogen Pharma by 1,594.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after acquiring an additional 3,125 shares during the period. Osaic Holdings Inc. increased its holdings in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Urogen Pharma by 422.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after purchasing an additional 5,571 shares during the last quarter. Creative Planning acquired a new stake in shares of Urogen Pharma during the third quarter worth about $208,000. Finally, Orion Porfolio Solutions LLC purchased a new stake in Urogen Pharma in the third quarter valued at approximately $220,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on URGN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, January 21st. Wall Street Zen raised Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a report on Friday, January 23rd. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Urogen Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $33.29.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.